Detects IgM antibodies against cardiolipin, used in evaluating antiphospholipid syndrome alongside clinical findings and other tests. This tests the IgM antibody class rather than IgG. The result is interpreted as part of an antiphospholipid evaluation, not as proof of a clotting disorder or an explanation for pregnancy complications on its own.

Screens for antibodies against cell nuclei to help evaluate autoimmune disorders; positive results require clinical interpretation. ANA is a broad autoimmune screen rather than a test for one specific disease. If antibodies are detected, further targeted testing may be appropriate; a positive screening result is not itself a diagnosis.

Detects IgG antiphospholipid antibodies; the specific antibody targets depend on the laboratory assay. The label describes an antibody group but does not identify all antigens included in the assay. Confirm the panel components so that the result is not mistaken for a complete antiphospholipid syndrome evaluation.

Detects IgM antiphospholipid antibodies; the specific antibody targets depend on the laboratory assay. This is the IgM component of the listed antiphospholipid antibody assessment. The laboratory’s antigen targets and reporting method must be confirmed before comparing it with other antiphospholipid tests or interpreting it clinically.